Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03454243 · ClinicalTrials.gov registry record · Early Phase 1
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
A Early Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03454243: Clinical Trial Early Phase 1 study, sponsored by Hoffmann-La Roche.
NCT03454243 is a Early Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03454243, a Early Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of RXDX 106.
Primary Outcome
Determine dose-limiting toxicities of RXDX-106
Interventions
- DRUG RXDX-106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2018-06-05 |
| Phase | Early Phase 1 |
Why NCT03454243 stopped before completion
NCT03454243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which RXDX-106 is the first listed.
NCT03454243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03454243 about?
NCT03454243 is a clinical study titled "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynami...
What is the current status of trial NCT03454243?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-02-15. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT03454243?
The interventions under investigation include: RXDX-106 (DRUG).
Who is sponsoring clinical trial NCT03454243?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03454243's enrollment target sits among peer trials
1 1985th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI